Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Live webcasts of these presentations can be accessed by visiting “Investor Events” on the Investor Relations section of the Wave Life Sciences website: ...

Shares of Arrowhead Pharmaceuticals ($ARWR) surged as much as 22% in pre-market trading on Tuesday after announcing a $825 ...

GRAND CAYMAN, CAYMAN ISLANDS, . (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA ...

The company is working with a Nucleic Acid Therapy Accelerator in the U.K. to more quickly develop cancer drugs.

Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support ...

GRAND CAYMAN, Cayman Islands, November 22, 2024 - Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...

RAG-21 is an siRNA therapy specifically designed to target FUS -ALS, one of the most aggressive subtype of ALS. By leveraging RNA interference (RNAi), RAG-21 safely and effectively reduces FUS protein ...